Sodium oxybate - Avadel Pharmaceuticals
Alternative Names: FT-218; LUMRYZ; Micropump® sodium oxybate; ON-SXBLatest Information Update: 14 Jun 2025
At a glance
- Originator Flamel Technologies
- Developer Avadel Pharmaceuticals
- Class Butyric acids; Hydroxybutyrates; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Yes - Narcolepsy; Idiopathic hypersomnia
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Narcolepsy
- Phase III Idiopathic hypersomnia
Most Recent Events
- 05 Jun 2025 Sodium oxybate - Avadel Pharmaceuticals receives Orphan Drug status for Idiopathic hypersomnia in USA
- 15 May 2025 Planned Prescription Drug User Fee Act (PDUFA) date for Narcolepsy (In children) in USA (PO) is 2024-09-07
- 06 May 2025 Federal Circuit decision allows Avadel to seek and be granted uS FDA approval for LUMRYZ in Idiopathic hypersomnia